| Literature DB >> 31736474 |
Tao Li1,2, Fu-Dong Fu1, Chang-Jing Wu1, Feng Qin1, Run Wang3, Jiu-Hong Yuan1,2.
Abstract
This study aimed to explore whether and how anti-lysyl oxidase (anti-LOX) combined with a vacuum device (VD) could promote penile lengthening and to evaluate the effect on erectile function. This study was performed on four groups of adult rats: control, anti-LOX, VD (negative pressure value of -300 mmHg), and anti-LOX + VD. Penile length was measured by a modified VD method and verified on exposed length data. Intracavernous pressure (ICP) and maximum ICP/mean arterial pressure (MAP) ratio were recorded to assess erectile function. For corpus cavernosum, LOX activity and concentrations of pyridinoline, desmosine, hydroxyproline, and elastin were analyzed; transmission electron microscope and Hart's elastin staining were performed to monitor microstructural changes. Anti-LOX and VD significantly lengthened the penis by 10.8% (3.75 mm) and 8.2% (2.48 mm) compared with the control group, respectively, while anti-LOX + VD achieved the longest penile size (40.58 ± 0.40 mm) which was 17.4% longer than the control group (34.58 ± 0.54 mm). After 1-week washout, no penile retraction was observed. Meanwhile, exposed penile length data confirmed that the penis in the anti-LOX + VD group was also significantly longer. Anti-LOX inhibited LOX activity to reduce pyridinoline level, which led the penile tunica albuginea remodeling. However, it had no effect on hydroxyproline, desmosine, and elastin levels. Moreover, anti-LOX had no impact on erectile function, which was determined by ICP and ICP/MAP ratio. These results suggest that anti-LOX elongates the penis by reducing pyridinoline, which induces tunica albuginea remodeling. This lengthening effect was more obvious when combined with a VD. All procedures had no impact on erectile function.Entities:
Keywords: anti-lysyl oxidase; crosslinking; penile lengthening; tunica albuginea remodeling; vacuum device
Mesh:
Substances:
Year: 2020 PMID: 31736474 PMCID: PMC7523611 DOI: 10.4103/aja.aja_120_19
Source DB: PubMed Journal: Asian J Androl ISSN: 1008-682X Impact factor: 3.285
Data collection
| Primary penile length (mm) | 31.17±0.11 | 31.08±0.15 | 31.25±0.11 | 31.08±0.33 | 0.9186 |
| Penile length (mm) | 34.58±0.54 | 38.33±0.36*** | 37.42±0.33*** | 40.58±0.40*** | <0.0001 |
| Penile length a week later (mm) | 34.83±0.59 | 38.50±0.32*** | 37.33±0.48*** | 41.00±0.37*** | <0.0001 |
| Exposed penile length (mm) | 31.92±0.33 | 35.33±0.31*** | 34.17±0.38*** | 36.50±0.26*** | <0.0001 |
| Rats’ final weight (g) | 440.83±14.76 | 430.83±12.58 | 420.50±11.21 | 424.17±8.11 | 0.6467 |
| Excised penile weight (mg) | 290.17±4.05 | 295.15±3.92 | 293.03±4.49 | 297.73±3.39 | 0.5924 |
| Dorsal-ventral length (mm) | 3.48±0.06 | 3.56±0.11 | 3.59±0.10 | 3.59±0.05 | 0.7520 |
| Lateral-lateral length (mm) | 3.37±0.03 | 3.35±0.11 | 3.43±0.07 | 3.42±0.04 | 0.8263 |
| Basic ICP (mmHg) | 6.69±0.67 | 6.66±0.31 | 6.81±0.23 | 6.95±0.15 | 0.9511 |
| ICP (mmHg) | 67.06±5.13 | 67.48±4.60 | 72.55±2.76 | 74.44±1.97 | 0.4512 |
| MAP (mmHg) | 109.07±5.77 | 118.02±5.12 | 128.73±6.79 | 120.74±2.36 | 0.1017 |
| ICP/MAP ratio | 0.62±0.04 | 0.57±0.03 | 0.57±0.02 | 0.62±0.02 | 0.4297 |
P values were calculated by ANOVA analysis for the difference among the four groups. ***P<0.0001, difference compared with control group. ICP: intracavernous pressure; MAP: mean arterial pressure; LOX: lysyl oxidase; VD: vacuum device aspiration with negative pressure of -300 mmHg
Penile length comparison in relative and percentage value ([longer−shorter]/shorter)
| Anti-LOX (mm, %) | 3.75 (10.8) | 0 | 0.91 (2.4) | 2.25 (5.9) |
| VD (mm, %) | 2.48 (8.2) | 0.91 | 0 | 3.16 (8.4) |
| Anti-LOX + VD (mm, %) | 6.00 (17.4) | 2.25 (5.9) | 3.16 (8.4) | 0 |
LOX: lysyl oxidase; VD: vacuum device
Penile length a week later comparison in relative and percentage value ([longer−shorter]/shorter)
| Anti-LOX (mm, %) | 3.67 (10.5) | 0 | 1.17 (3.1) | 2.5 (6.5) |
| VD (mm, %) | 2.50 (7.2) | 1.17 (3.1) | 0 | 3.67 (9.8) |
| Anti-LOX + VD (mm, %) | 6.17 (17.7) | 2.50 (6.5) | 3.67 (9.8) | 0 |
Exposed penile length comparison in relative and percentage value ([longer−shorter]/shorter)
| Anti-LOX (mm, %) | 3.41 (10.7) | 0 | 1.16 (3.0%) | 1.17 (3.3%) |
| VD (mm, %) | 2.25 (7.1) | 1.16 (3.0%) | 0 | 2.33 (6.8%) |
| Anti-LOX + VD (mm, %) | 4.58 (14.4) | 1.17 (3.3%) | 2.33 (6.8%) | 0 |